IASIS PHARMA has successfully launched COVED® to the Greek market.
COVED® (Bisphosphonates, combinations) is a fixed dose combination of two active ingredients:
Alendronic acid (as alendronate sodium trihydrate) (70mg) & Cholecalciferol (Vitamin D3) (5.600 I.U).
COVED® 70 mg / 5,600 IU is indicated for the treatment of postmenopausal osteoporosis in women at risk of vitamin D insufficiency. COVED® reduces the risk of both vertebral and hip fractures.
COVED® is available in a 4 tablet-pack (BTx4). Recommended dose: one tablet once weekly.